PD1/PDL1 and CTLA-4 were indispensable components of immune checkpoint inhibitors; PD1/PDL1 or CTLA-4 checkpoint blockade therapy exhibited potential therapeutic effects on HCC patients30. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.